A Phase 3 interventional study of ITI-007 and Placebo in Agitation in Dementia, Including Alzheimer's Disease, sponsored by Intra-Cellular Therapies, Inc.. Terminated at 26 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2021-06-29.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
First submitted before Intra-Cellular Therapies, Inc. became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.
Drug: ITI-007
Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
Drug: Placebo
Change From Baseline in the Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)
The Cohen-Mansfield Agitation Inventory-Community Version is a 37-item scale for identifying and quantifying agitated behaviors in elderly persons in a community setting. Each item is rated from 1='Never' to 7='Several Times Per Hour'. Each category contains a pre-specified subset of the CMAI-C items. The score of each category is the sum of the CMAI-C items included in that category: Aggressive Behavior-Sum of 9 CMAI-C items, ranges from 9 to 63; Non-Aggressive Agitated Behavior-Sum of 6 CMAI-C items, ranges from 6 to 42; Verbally Agitated Behavior-Sum of 4 CMAI-C items, ranges from 4 to 28.
Time frame: 4 weeks (28 Days)
Change From Baseline in the Clinical Global Impression Scale for Severity of Illness (CGI-S)
The CGI scale for Severity of Illness is a standardized assessment tool to rate the overall severity of illness and efficacy of medication. CGI-S of Agitation and CGI-S of Aggression will be used in this study as a measure of efficacy. Scores on the CGI-S range from 1 (not ill at all) to 7 (among the most extremely ill).
Time frame: 4 weeks (28 Days)
| Milestone | ITI-007 9 mg | Placebo |
|---|---|---|
| Started | 86 | 89 |
| Completed | 70 | 84 |
| Not completed | 16 | 5 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Study terminated by sponsor | 2 | 2 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Other | 2 | 2 |
The Cohen-Mansfield Agitation Inventory-Community Version is a 37-item scale for identifying and quantifying agitated behaviors in elderly persons in a community setting. Each item is rated from 1='Never' to 7='Several Times Per Hour'. Each category contains a pre-specified subset of the CMAI-C items. The score of each category is the sum of the CMAI-C items included in that category: Aggressive Behavior-Sum of 9 CMAI-C items, ranges from 9 to 63; Non-Aggressive Agitated Behavior-Sum of 6 CMAI-C items, ranges from 6 to 42; Verbally Agitated Behavior-Sum of 4 CMAI-C items, ranges from 4 to 28.
| score on a scale | 9 mg ITI-007 | Placebo |
|---|---|---|
| Aggressive Agitated Behavior | -1.0 ± 0.37 | -2.3 ± 0.33 |
| Non-Aggressive Agitated Behavior | -4.1 ± 0.72 | -3.9 ± 0.65 |
| Verbally Agitated Behavior | -2.9 ± 0.49 | -2.3 ± 0.45 |
The CGI scale for Severity of Illness is a standardized assessment tool to rate the overall severity of illness and efficacy of medication. CGI-S of Agitation and CGI-S of Aggression will be used in this study as a measure of efficacy. Scores on the CGI-S range from 1 (not ill at all) to 7 (among the most extremely ill).
| score on a scale | 9 mg ITI-007 | Placebo |
|---|---|---|
| CGI-S Aggression | -0.4 ± 0.12 | -0.6 ± 0.10 |
| CGI-S Agitation | -0.8 ± 0.11 | -0.9 ± 0.10 |
Collected over 4 weeks of double blind treatment.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 9 mg ITI-007 | 0/86 (0%) | 2/86 (2.3%) | 13/86 (15.1%) |
| Placebo | 0/89 (0%) | 1/89 (1.1%) | 8/89 (9%) |
| Event | 9 mg ITI-007 | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 1/86 | 0/89 |
| Ammonia IncreasedInvestigations | 1/86 | 0/89 |
| AcarodermatitisInfections and infestations | 0/86 | 1/89 |
| Event | 9 mg ITI-007 | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 4/86 | 0/89 |
| FallInjury, poisoning and procedural complications | 4/86 | 1/89 |
| NauseaGastrointestinal disorders | 3/86 | 0/89 |
| SomnolenceNervous system disorders | 0/86 | 3/89 |
| VomitingGastrointestinal disorders | 2/86 | 0/89 |
| ConstipationGastrointestinal disorders | 2/86 | 0/89 |
| HeadacheNervous system disorders | 2/86 | 1/89 |
| Upper respiratory tract infectionInfections and infestations | 2/86 | 2/89 |
| Abdominal pain upperGastrointestinal disorders | 0/86 | 2/89 |
Safety Analysis Set
| Age, Continuous(years) | 9 mg ITI-007 | Placebo | Total |
|---|---|---|---|
| Mean | 75.6 ± 8.64 | 74.1 ± 8.61 | 74.8 ± 8.63 |
| Sex: Female, Male(Participants) | 9 mg ITI-007 | Placebo | Total |
|---|---|---|---|
| Female | 44 | 57 | 101 |
| Male | 42 | 32 | 74 |
| Race/Ethnicity, Customized(Participants) | 9 mg ITI-007 | Placebo | Total |
|---|---|---|---|
| White | 73 | 75 | 148 |
| Black or African American | 10 | 10 | 20 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Multiple | 0 | 1 | 1 |
| Unknown | 0 | 1 | 1 |
| CMAI-C(units on a scale) | 9 mg ITI-007 | Placebo | Total |
|---|---|---|---|
| CMAI-C Aggressive Behavior | 13.28 ± 4.51 | 14.08 ± 5.92 | 13.69 ± 5.27 |
| CMAI-C Non-Aggressive Agitated Behavior | 17.20 ± 7.42 | 17.46 ± 7.05 | 17.33 ± 7.22 |
| CMAI-C Verbally Agitated Behavior | 15.37 ± 4.95 | 15.65 ± 5.02 | 15.51 ± 4.98 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Jan 2019, 29 months.
Results were first posted in Jun 2021, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Aberrant Motor Behavior in Dementia
Intra-Cellular Therapies, Inc. →